Accessibility Menu
Theracryf Plc logo

Theracryf Plc(LSE) TCF

Market Cap£4.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-99%
5 Year-96%
1 Year-16%
1 Month-10%
£0.00
-5.26%
-0.00Today
Theracryf Plc last closing stock price
MetricPriceDate
Last closeGBX 0.192026-08-20
Theracryf Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.56%GBX 0.202026-08-13
1 month-9.52%GBX 0.212026-07-21
3 month-17.39%GBX 0.232026-05-22
Year to date-5%GBX 0.202025-12-31
1 year-15.56%GBX 0.232025-08-20
3 year-92.4%GBX 2.502023-08-21
5 year-96.27%GBX 5.102021-08-20
Since inception-99.45%GBX 0.352015-10-21

Theracryf Plc Financials at a Glance

Market Cap

£4.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£4.93M

EPS (TTM)

-£0.00

P/E Ratio

-1.46

Dividend

£0.00

Beta (Volatility)

0.27 (Low)

Price

£0.00

Volume

1,885,000

Open

£0.00

Previous Close

£0.00

Daily Range

£0.00 - £0.00

52-Week Range

£0.00 - £0.00

Estimated Earnings Date

Dec 17, 2026

TCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theracryf Plc

Theracryf Plc is a clinical-stage biotechnology firm focused on developing innovative treatments for oncological diseases and brain disorders. The company is advancing its primary therapeutic asset, SFX-01, through various clinical trials, aiming to address significant unmet medical needs.

Products and Services
  • SFX-01 for metastatic breast cancer in Phase II trials
  • Orexin 1 antagonist targeting addiction and anxiety in late preclinical stage
  • Atypical dopamine transporter inhibitor for fatigue and narcolepsy in late preclinical stage
Growth Outlook
  • Pipeline includes multiple assets targeting high-prevalence conditions
  • Recent clinical advancements position the company for potential market entry
  • Strong focus on research and development to drive future growth
Financial Highlights
  • Recent quarterly net income of -£1.31 million, reflecting ongoing investment in R&D
  • Cash and short-term investments totaled £3.5 million as of September 2025
  • Current ratio of 2.29 indicates strong liquidity position
Theracryf Plc, incorporated in 2014 and headquartered in Nether Alderley, United Kingdom, has undergone a rebranding from Evgen Pharma plc to its current name in April 2024. The company is dedicated to addressing critical health challenges through its innovative pipeline, which includes SFX-01, currently in advanced clinical trials. The focus on oncological diseases and neurodevelopmental conditions highlights the company's commitment to improving patient outcomes. With a solid financial foundation and a strategic approach to research and development, Theracryf Plc is positioned to make significant contributions to the biotechnology sector.
AI Generated • Aug 4, 2026

Industry

Biotechnology

Sector

Health Care

Employees

9

CEO

Huw Jones, PhD

Website

www.evgen.com

Headquarters

Nether Alderley, CH SK10 4TG, GB

TCF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-37.30%

Return on Capital

-35.58%

Return on Assets

-30.36%

Earnings Yield

-68.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£4.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.15B

Volume

1.89M

Avg. Volume

2.52M

Financials (TTM)

Gross Profit

-£906.00K

Operating Income

-£5.60M

EBITDA

-£5.46M

Operating Cash Flow

-£4.80M

Capital Expenditure

£0.00

Free Cash Flow

-£4.80M

Cash & ST Invst.

£3.50M

Total Debt

£0.00

Theracryf Plc Performance Analysis

Theracryf Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31GBP 0N/A
20232023-03-31GBP 442,000N/A
20242024-03-31GBP 396,000-10.4%
20252025-03-31GBP 0N/A
Theracryf Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-03-31-100.0%
Q22024-09-30N/A
Q42025-03-31N/A
Q22025-09-30N/A
Theracryf Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31GBP -0.01N/A
20232023-03-31GBP -0.0148.5%
20242024-03-31GBP -0.01-22.4%
20252025-03-31GBP -0.00-68.4%
Theracryf Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-03-31-15.1%
Q22024-09-3026.2%
Q42025-03-3175.6%
Q22025-09-30100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

£0.00

-100.0%

Gross Profit

-£4.00K

-101.0%

Gross Margin

0.00%

N/A

Market Cap

£4.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£453.67K

N/A

Employees

9

N/A

Net Income

-£1.31M

+10.0%

EBITDA

-£1.31M

+9.9%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

£3.50M

-6.2%

Total Debt

£0.00

N/A

Accounts Receivable

£666.00K

+14.4%

Inventory

£0.00

N/A

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-30.36%

N/A

Return on Invested Capital

-46.75%

N/A

Free Cash Flow

-£699.00K

+45.0%

Operating Cash Flow

-£699.00K

+45.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
N4P.LN4 Pharma Plc
£0.00+0.00%
CRTX.LCRISM Therapeutics Corporation
£0.11+0.00%
PRM.LProteome Sciences plc
£0.02-5.29%
TRX.LTissue Regenix Group plc
£0.07+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About TCF

What is the current price of Theracryf Plc?

Theracryf Plc is trading at £0.00 per share.

What is the 52-week range for Theracryf Plc?

Over the past 52 weeks, Theracryf Plc has traded between £0.00 and £0.00.

How much debt does Theracryf Plc have?

As of the most recent reporting period, Theracryf Plc reported total debt of £0.00.

How much cash does Theracryf Plc have on hand?

Theracryf Plc reported £2.11M in cash and cash equivalents in its most recent financial results.

What is Theracryf Plc’s dividend yield?

Theracryf Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services